Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma
- 1 January 2016
- journal article
- case report
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 63 (10), 905-912
- https://doi.org/10.1507/endocrj.ej16-0161
Abstract
The anti-programmed cell death-1 monoclonal antibody (mab), nivolumab has recently been approved for the treatment of unresectable or metastatic malignant melanoma and non-small-cell lung cancers in Japan. Ipilimumab, an anti-cytotoxic T lymphocyte antigen-4 mab for malignant melanoma that was approved earlier than nivolumab in Western countries, is known to frequently cause endocrine immune-related adverse events such as hypophysitis and thyroid dysfunction. We herein report a patient with advanced melanoma who appeared to develop hypophysitis as a consequence of the inhibition of PD-1 by nivolumab. One week after the 6th administration of nivolumab, the patient developed progressive fatigue and appetite loss. Laboratory data on admission for the 7th administration of nivolumab showed eosinophilia and hyponatremia. Since ACTH and cortisol levels were low, nivolumab was discontinued and a large dose of hydrocortisone (100 mg/d) was promptly administered intravenously. A magnetic resonance imaging scan revealed the mild enlargement of the anterior pituitary gland and thickening of the stalk with homogenous contrast. A detailed assessment of anterior pituitary functions with hypothalamic hormone challenges showed that hormonal secretions other than ACTH and TSH were normal. With a replacement dose of hydrocortisone (20 mg/d), the 7th administration of nivolumab was completed without exacerbating the patient's general condition. The present report provides the first detailed endocrinological presentation of nivolumab-induced hypophysitis showing the enlargement of the pituitary gland and stalk in a malignant melanoma patient in Japan. Oncologists and endocrinologists need to be familiar with potentially life-threatening hypophysitis induced by immune-checkpoint inhibitors.Keywords
This publication has 23 references indexed in Scilit:
- The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literatureActa Endocrinologica, 2014
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypothesesActa Endocrinologica, 2013
- Thyroid Dysfunction as an Unintended Side Effect of Anticancer DrugsThyroid®, 2013
- Endocrine Side Effects Induced by Immune Checkpoint InhibitorsJournal of Clinical Endocrinology & Metabolism, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- A novel clinical entity, IgG4-related disease (IgG4RD): general concept and detailsModern Rheumatology, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Autoimmune HypophysitisEndocrine Reviews, 2005
- PD-1: an inhibitory immunoreceptor involved in peripheral toleranceTrends in Immunology, 2001
- Lymphocytic Infundibuloneurohypophysitis as a Cause of Central Diabetes InsipidusNew England Journal of Medicine, 1993